KR101561652B1 - Sdf-1 결합형 c형 핵산분자 - Google Patents

Sdf-1 결합형 c형 핵산분자 Download PDF

Info

Publication number
KR101561652B1
KR101561652B1 KR1020137020754A KR20137020754A KR101561652B1 KR 101561652 B1 KR101561652 B1 KR 101561652B1 KR 1020137020754 A KR1020137020754 A KR 1020137020754A KR 20137020754 A KR20137020754 A KR 20137020754A KR 101561652 B1 KR101561652 B1 KR 101561652B1
Authority
KR
South Korea
Prior art keywords
nucleic acid
sdf
nucleotide
rna
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137020754A
Other languages
English (en)
Korean (ko)
Other versions
KR20130090428A (ko
Inventor
웨르너르 퍼르쉬케이
플로리안 야로슈
디르크 율베르그
스벤 클루스만
클라우스 부크너르
크리스티안 매쉬
니꼴 딘세
Original Assignee
녹손 파르마 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 녹손 파르마 아게 filed Critical 녹손 파르마 아게
Publication of KR20130090428A publication Critical patent/KR20130090428A/ko
Application granted granted Critical
Publication of KR101561652B1 publication Critical patent/KR101561652B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
KR1020137020754A 2006-07-18 2007-07-18 Sdf-1 결합형 c형 핵산분자 Active KR101561652B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06014957.2 2006-07-18
EP06014957 2006-07-18
PCT/EP2007/006387 WO2008009437A2 (en) 2006-07-18 2007-07-18 Sdf-i binding nucleic acids

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020097000923A Division KR101466931B1 (ko) 2006-07-18 2007-07-18 Sdf-1 결합형 b형 핵산분자

Publications (2)

Publication Number Publication Date
KR20130090428A KR20130090428A (ko) 2013-08-13
KR101561652B1 true KR101561652B1 (ko) 2015-10-20

Family

ID=38947372

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137020754A Active KR101561652B1 (ko) 2006-07-18 2007-07-18 Sdf-1 결합형 c형 핵산분자
KR1020097000923A Active KR101466931B1 (ko) 2006-07-18 2007-07-18 Sdf-1 결합형 b형 핵산분자

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097000923A Active KR101466931B1 (ko) 2006-07-18 2007-07-18 Sdf-1 결합형 b형 핵산분자

Country Status (16)

Country Link
US (5) US8314223B2 (enExample)
EP (1) EP2041282B1 (enExample)
JP (1) JP5380287B2 (enExample)
KR (2) KR101561652B1 (enExample)
CN (2) CN101506364B (enExample)
AR (1) AR061929A1 (enExample)
AU (1) AU2007276435C1 (enExample)
BR (1) BRPI0714844B8 (enExample)
CA (1) CA2658267C (enExample)
DK (1) DK2041282T3 (enExample)
ES (1) ES2663404T3 (enExample)
MX (1) MX2009000656A (enExample)
PL (1) PL2041282T3 (enExample)
PT (1) PT2041282T (enExample)
RU (1) RU2590709C2 (enExample)
WO (1) WO2008009437A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009000656A (es) 2006-07-18 2009-03-25 Noxxon Pharma Ag Acidos nucleicos que se fijan a sdf-i.
BRPI0815094B8 (pt) * 2007-08-06 2023-04-18 Noxxon Pharma Ag Uso de uma molécula de ácido l-nucleico ligada a sdf-1
JP5463621B2 (ja) * 2008-02-27 2014-04-09 ソニー株式会社 標的物質の定量方法
EP2304031A2 (en) * 2008-06-11 2011-04-06 Bionucleon S.r.l. Inhibition of hrp-3 using modified oligonucleotides
TWI578992B (zh) * 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類
WO2012025251A1 (en) * 2010-08-27 2012-03-01 Noxxon Pharma Ag Nucleic acids for treatment of chronic complications of diabetes
EP2613789B1 (en) * 2010-09-09 2018-04-18 Noxxon Pharma AG Sdf-1 binding nucleic acids and the use thereof in cancer treatment
US20140057970A1 (en) * 2010-10-29 2014-02-27 Frank Schwobel Use of Hepcidin Binding Nucleic Acids for Depletion of Hepcidin From the Body
EP2872147B1 (en) 2012-07-13 2022-12-21 Wave Life Sciences Ltd. Method for making chiral oligonucleotides
WO2016096640A2 (en) * 2014-12-17 2016-06-23 Cancer Research Technology Ltd Anti-cxcl12 antibody molecules and their uses
EP3443095A1 (en) * 2016-04-15 2019-02-20 Noxxon Pharma AG Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors
US11221270B2 (en) * 2018-02-27 2022-01-11 Kevan M Evans Method and apparatus for detecting slow leaks
WO2021178923A1 (en) 2020-03-06 2021-09-10 Drinksavvy, Inc. Devices and methods for detecting a target analyte of interest
EP4173639A4 (en) 2020-06-26 2024-03-13 RaQualia Pharma Inc. Method for selecting cancer patient for which combination therapy of retinoid and cancer treatment agent will be effective, and combined drug of retinoid and cancer treatment agent
WO2023154452A1 (en) 2022-02-11 2023-08-17 Waypoint Bio, Inc. Cellular staining probes for analyte detection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032143A1 (en) 2004-09-23 2006-03-30 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
JPH06508022A (ja) * 1991-02-21 1994-09-14 ギリアド　サイエンシズ，インコーポレイテッド 生体分子に特異的なアプタマーおよび生産方法
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
ATE333896T1 (de) * 1998-03-24 2006-08-15 Chugai Pharmaceutical Co Ltd Vaskularisierungsinhibitoren
US6670149B1 (en) * 1999-03-01 2003-12-30 Millennium Pharmaceuticals, Inc. TWIK-5 potassium channel nucleic acids and uses therefor
US6949243B1 (en) 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
EP1133988A1 (en) * 2000-03-11 2001-09-19 Biognostik Gesellschaft für biomolekulare Diagnostik mbH Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
KR100598309B1 (ko) 2001-06-07 2006-07-10 케모센트릭스, 인크. 세포 이동성 검사
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
GB0225833D0 (en) 2002-11-06 2002-12-11 Univ Leeds Nucleic acid ligands and uses therefor
ATE474046T1 (de) * 2004-11-29 2010-07-15 Noxxon Pharma Ag Vasopressin bindende l-nukleinsäure
EP1993584B1 (en) 2006-02-02 2012-05-30 Allergan, Inc. Inhibitors of CXCR4 activity for use in the treatment of ocular disorders
MX2009000656A (es) 2006-07-18 2009-03-25 Noxxon Pharma Ag Acidos nucleicos que se fijan a sdf-i.
SG10201608268RA (en) 2006-10-02 2016-11-29 Medarex Llc Human antibodies that bind cxcr4 and uses thereof
AU2007325029B2 (en) 2006-11-30 2013-09-12 The Regents Of The University Of California Methods for treating and diagnosing fibrotic and fibroproliferative diseases
BRPI0815094B8 (pt) 2007-08-06 2023-04-18 Noxxon Pharma Ag Uso de uma molécula de ácido l-nucleico ligada a sdf-1
US20090274687A1 (en) 2008-05-02 2009-11-05 University Of Miami Attenuation of hypoxia induced cardiovascular disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032143A1 (en) 2004-09-23 2006-03-30 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Journal of Neuroscience Vol.23(4):1360-1371 (2003. 02. 15.)

Also Published As

Publication number Publication date
BRPI0714844B1 (pt) 2019-10-01
US9035038B2 (en) 2015-05-19
PT2041282T (pt) 2018-03-13
BRPI0714844A2 (pt) 2013-11-26
KR20090039717A (ko) 2009-04-22
US20130041019A1 (en) 2013-02-14
JP2009543567A (ja) 2009-12-10
PL2041282T3 (pl) 2018-07-31
US20150232853A1 (en) 2015-08-20
RU2009105494A (ru) 2010-08-27
MX2009000656A (es) 2009-03-25
EP2041282B1 (en) 2018-01-03
JP5380287B2 (ja) 2014-01-08
US20180163207A1 (en) 2018-06-14
KR20130090428A (ko) 2013-08-13
CN103555725B (zh) 2017-05-24
WO2008009437A3 (en) 2008-03-27
WO2008009437A2 (en) 2008-01-24
ES2663404T3 (es) 2018-04-12
US9822369B2 (en) 2017-11-21
CN101506364B (zh) 2013-10-30
US8314223B2 (en) 2012-11-20
CA2658267A1 (en) 2008-01-24
RU2590709C2 (ru) 2016-07-10
AU2007276435A1 (en) 2008-01-24
KR101466931B1 (ko) 2014-12-02
EP2041282A2 (en) 2009-04-01
CN101506364A (zh) 2009-08-12
HK1131184A1 (en) 2010-01-15
DK2041282T3 (en) 2018-04-16
AU2007276435C1 (en) 2013-06-13
BRPI0714844B8 (pt) 2023-04-18
AR061929A1 (es) 2008-10-01
US20210139909A1 (en) 2021-05-13
US20110112172A1 (en) 2011-05-12
AU2007276435B2 (en) 2013-01-24
CN103555725A (zh) 2014-02-05
CA2658267C (en) 2021-03-30

Similar Documents

Publication Publication Date Title
KR101561652B1 (ko) Sdf-1 결합형 c형 핵산분자
US9988636B2 (en) SDF-1 binding nucleic acids and the use thereof
KR101572893B1 (ko) Mcp-1 결합형 3형 핵산
AU2013200034A1 (en) Sdf-i binding nucleic acids
HK1131184B (en) Sdf-i binding nucleic acids
HK1144956B (en) Sdf-1 binding nucleic acids and the use thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20130806

Application number text: 1020097000923

Filing date: 20090116

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131028

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140828

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20150728

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20151013

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20151014

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20180927

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20180927

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20190918

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20190918

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20200923

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20210917

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20220920

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20230915

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee